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Abstract
For the last few years, the number of immunocompromised individuals is growing
fast, due to more intensive antitumor therapy, transplantations and the concomitant
immunosuppressive therapy, and the HIV epidemic, as well. Immunosuppressed pa‐
tients very often are affected with nosocomial infections in hospitals, and with infec‐
tions in the society. The defense from viral diseases depends mainly on the immune
system. When there is immune deficiency, the illness is taking severely longer and has
complicated outcome. Usually immunocompromised individuals have one or more
defects in the defensive mechanisms and leading cause of death is infection.The virus‐
es taking part in this process are Epstein Barr virus (EBV), Cytomegalovius (CMV),
Herpes simplex viruses (HSV1, HSV2), Varicella zoster virus (VZV), Hepatitis B virus
(HBV), Hepatitis C virus (HCV), and Human Polyomaviruses (BKV, JC). Many virus‐
es (HIV, CMV, EBV) are depressing the immune resistance and are leading to co-in‐
fections with other microbial agents. Some viruses (HSV1/2, HPV, CMV, EBV, BKV,
JC) are at latent condition in the infected persons for life. They become activated when
decline in the immunity occurs, leading to serious illnesses. For this reason, accurate
screening and prompt and precise diagnosis can be performed to prevent exacerba‐
tion of diseases and provide appropriate treatment.
Keywords: immunosupression, immunocompromised individuals, transplantation,
viral infections
1. Introduction
According to several studies during the last few years, a tendency toward decreasing immune
protection in human population has been under review. In the second half of the 20th century,
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the number of immunocompromised individuals is growing fast, due to more intensive
antitumor therapy, transplantations, and the concomitant application of immunosuppressors
and the HIV epidemic, as well. New syndromes and diseases appear, such as post-transplant
lymphoproliferative disease (PTLD), caused in most cases by Epstein-Barr virus (EBV), and
pneumonia by Cytomegalovirus (CMV). Other viruses taking part in this process are Herpes
simplex viruses (HSV1, HSV2), Varicella zoster virus (VZV), Hepatitis B virus (HBV), Hepatitis
C virus (HCV), and Human Polyomaviruses (BKV, JC). Usually immunocompromised
individuals have one or more defects in the defensive mechanisms and leading cause of death
is infection. The problem with viral causers of infections and diseases has become complicated
for a few reasons:
1. The defense from viral diseases depends mainly on the immune system. When there is
immune deficiency, the illness is taking severely longer from its normal course and has
complicated outcome. In such patients, the disease often becomes chronic or lead to
neoplasms.
2. Many viruses (HIV, CMV, EBV) are depressing the immune resistance and are leading to
co-infections with other microbial agents.
3. Some viruses (HSV1/2, HPV, CMV, EBV, BKV, JC) are at latent condition in the infected
persons for life. They become activated when decline in the immunity occurs, leading to
serious illnesses.
4. In seronegative pregnant women and those with immune deficiency, the risk for congen‐
ital infections rises substantially.
The immune deficiency can be primary (congenital) and secondary (acquired).
Primary immunodeficiency is developed because of genetic block in differentiation of
immunocompetent cells and impairment of immune mechanisms in antibody and/or T-
lymphocytes production. There are three groups of primary immune deficiency:
1. Combined immune deficiency affecting T and B cell population with insufficient cellular
and humoral immunity (hypogammaglobulinaemia of Glanzmann-Riniker).
2. Immunodeficiency due to a defect in the function of B cells with hypo- and agammaglo‐
bulinaemia and especially IgA deficiency (agammaglobulinaemia of Bruton, common
variable hypogammaglobulinaemia).
3. Immunodeficiency based on T cell insufficiency with thymus aplasia (DiGeorge Syn‐
drome), defect in α- and γ-interferon synthesis.
Other than the primary immune deficits mentioned above, there are others, such as defect in
the enzyme assuring purine nucleotides’ phosphorylation and structural defects in the 14th
chromosome.
The congenital B cell insufficiency leads to serious diseases after live vaccine application
(poliomyelitis, measles, mumps, rubella). There is affecting of central nervous system and
development of paresis and frequent recurrent viral infections of respiratory track. After
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infections caused by enteroviruses, encephalitis and myositis can occur. Chronic diarrhea is
typical in rotavirus infection.
The congenital T-cell insufficiency brings about systematic infections caused by different
viruses such as CMV, EBV, VZV, and by viruses of families ortho- and paramyxoviridae also.
Patients with interferon failure suffer from frequent respiratory diseases.
Secondary immune deficiency can be seen in:
1. Viral diseases as measles, mumps, and mononucleosis syndrome (EBV, CMV).
2. Autoimmune and malignant diseases, especially to the blood and reticuloendothelial
system (myeloid leukemia, lymphoid leukemia, multiple myelomas, Morbus of Hodgkin),
affecting T cell precursors and macrophages and causing deficiency in cell-mediated
immunity.
3. Renal failure and uremia in patients on hemodialysis.
4. Viral infections of the immune system (HIV) affecting the function of CD4+ T-helper cells,
humoral and cell-mediated immune response afterwords are suppressed.
5. Medical treatment with immunosuppressive therapy, treatment with glycocorticoids,
radiotherapy are affected barrier function of the epithelium of upper respiratory track and
intestinal mucosa. This results in severe respiratory and intestinal infections. Cell
proliferation is suppressed, leading to neutropenia, lymphopenia, monocytopenia. The
advance of PMN cells into the space of inflammation is also suppressed. There is also
difference in the sensitivity of macrophages to macrophage-activating cytokine (α-
interferons). Precursors of T cell and macrophages are affected, which leads to the
deficiency of cell-mediated immunity.
6. Organ transplantation and immunosuppressive therapy during post-transplant period.
Etiology and pathogenesis of viral infections in immunocompromised patients depends on
the type of the immune deficiency. Clinical disease usually includes nonspecific symptoms. In
most cases, it cannot be differentiated from organ rejection in patients with transplantation.
The specific laboratory virological and serological tests are important for diagnosis.
More significant viral infections and diseases in immunocompromised patients are described
below.
2. Epstein-Barr Virus (EBV)
EBV is a herpesvirus that is thought to infect up to 95% of the adult population. Primary
infection in childhood usually results in mild, self-limiting illness [1, 2]. Asymptomatic carriers
in childhood are often seen. Immunocompetent older children and adult patients get sick from
infectious mononucleosis with benign lymphoproliferation of B cells under the control of the
cytotoxic T cells and cellular immune response consisting of CD4+ and CD8+ T cells, which
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control both primary infection ant periodic reactivation that occur in all EBV-seropositive
persons [1, 3, 4]. The EBV causes nasopharyngeal carcinoma, Burkitt lymphoma, and other
lymphoepithelic tumors (non-Hodgkin’s lymphoma, B- and T-cellular lymphomas) [5].
Development of these diseases is based on some cellular factors, as well as 14th chromosome
translocation. Once infected with EBV, the virus persists latently in a person for life, in B cell
lymphocytes, and chronically replicating in the cells of the oropharynx [5, 6]. In patients with
HIV and transplanted ones, EBV becomes a main problem because of the inability of the
immune system to control B cell proliferation and immortalization. EBV infection is registered
in nearly 75% of transplanted recipients as the source usually is the donor. Contagion can also
occur after blood transfusion. In the course of the immunosuppression, the latent EBV infection
can be reactivated. Clinical disease represent mononuclear syndrome with temperature,
lymphadenopathy, hepatosplenomegaly and monocytosis. The central nervous system is
rarely involved with symptoms of serous meningitis, encephalitis, Guillen Barre syndrome.
The immunosuppression required to prevent graft rejection post-transplantation impairs T
cell immunity, potentially allowing for uncontrolled proliferation of EBV-infected B cells,
which may result in a spectrum of B cell proliferations that range from hyperplasia to true
lymphoma [7, 8]. In the initial stages of PTLD, prolypheration is polyclonal. With mutation
and selective growth, the lesion becomes oligoclonal and later, monoclonal. Lymphocytes from
patients treated with cyclosporine do not exhibit an appropriate T cell response to EBV-infected
B cells in vitro. The activity of natural killer cells is reduced for several months following
transplantation [9, 10].
PTLD is a well-recognized complication of both solid organ transplantation and allogeneic
hematopoietic stem cell transplantation (HSCT). It is one of the most common post-transplant
malignancies. In most cases, it is associated with EBV infection of B cells, either as a conse‐
quence of post-transplant reactivation of the virus or from primary EBV infection. The median
onset of disease in solid organ transplant population is 6 months and in hematopoietic stem
cell recipients 70–90 days [11, 12] after transplantation. The frequency of PTLD depends largely
on the type of transplant received and the immunosuppression that the particular transplant
requires [6, 11, 12]. Primary EBV infection may develop, such as in an EBV seronegative
recipient who received an allograft from an EBV-seropositive donor. This is recognized as
probably the most significant risk factor for developing PTLD and be higher in pediatric
transplant recipients [12]. The incidence ranged from 0.6%–2.1% in adult kidney recipients to
4.4%–6.9% in pediatric kidney recipients [12, 13] at different time after transplantation. Lung
and heart transplantation in adult population is associated with a relatively high rate of PTLD
with an incidence of approximately 5% or more [14]. After liver transplantation, reported rate
of incidence is approximately 1% in adult recipients and pediatric recipients [15]. In the setting
of allogeneic hematopoietic stem cell transplantation, PTLD rates vary greatly depending on
the conditioning regimen and the amount of T cell depletion. In pediatric recipients, PTLD
occurs in less than 1% of non-T-cell-depleted grafts from matched siblings, compared with as
high as 30% of patients with unrelated or HLA-mismatched donors when extensive T cell
depletion of the donor bone marrow is performed. Treatment of graft versus host disease with
antitimocyte globulin or anti-T-cell monoclonal antibodies is another risk factor for PTLD [16].
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According to the laboratory data, PTLD is characterized by leukopenia, thrombocytopenia,
atypical lymphocytosis, generalized lymphadenopathy. Also B-cell lymphoma, non-Hodg‐
kin’s lymphoma (90%), lung lymphoid hyperplasia and lymphoid interstitial pneumonia (after
lung transplantation), oral "hairy” leukoplakia (in association with HPV), and malignant
transformation are developed. Of note, PTLD may be very difficult to distinguish from
episodes of organ rejection and infection. Cell factors take part in the progress of PTLD, as well
as co-infection with CMV. Different clinical symptoms can go along with the functional
disorder. Mortality rate after solid-organ transplantation is more than 50% and after hemato‐
poietic stem cell transplantation early mortality rate approached 90% [17, 18].
PTLD is an often-fatal complication of transplanted patients. Early diagnosis is important.
Good medical practice requires elucidating the serological status of the patients for EBV before
transplantation or immunosuppression. ELISA and immunofluorescence are used. Those who
have latent infection have positive results for IgG against capsid antigen of the virus (VCA),
and in most cases, against nuclear Ag (EBNA). Patients with primary or activated latent
infection may have IgM and IgG anti EBV VCA, and high titer against early Ag (EA), usually
EBNA are not formed. Other special studies to confirm the diagnosis of PTLD include
immunophenotyping by flow cytometry or immunohistochemistry and molecular studies
such as fluorescent in situ hybridization for EBV early RNA (EBER). EBV PCR of peripheral
blood may be useful at the time of diagnosis and during follow-up as a method of monitoring
the patient’s response to treatment [18]. Surveillance by monthly PCR for circulating EBV DNA
may be appropriate in such high-risk settings as EBV-seromismatched (donor-positive,
recipient-negative) solid organ transplants and T cell depleted, HLA-mismatched stem cell
transplants [18, 19].
Reduction in immunosuppression remains the primary therapy and often results in permanent
disease eradication (19). Antiviral drugs are used (acyclovir, valacyclovir, famcyclovir,
gancyclovir) combined with immunotherapy with anti-B-cell antibodies or conventional
chemotherapy. Adoptive immunotherapy with EBV-specific donor T cells is highly effective.
There is some data for the prophylactic administration of gancyclovir before transplantation
and immunosuppression (20).
3. Cytomegalovirus (CMV)
CMV is a ubiquitous herpesvirus that infects majority of humans and is transmitted via saliva,
body fluids, cell, and tissue. Primary infection in immunocompetent individuals manifests as
an asymptomatic or self-limited febrile illness or as mononucleosa-like syndrome in childhood
and older age. The seroprevalence depends on the socioeconomic status and ranges from 30%–
97% in Europe and North America [2, 21]. Following primary viral replication in seronegative
individuals, CMV establishes non-replicative infection for life, named latency, in CD34+
myeloid progenitor cells as a major site [22] and in lymphoid organs and tissues as well (23).
Various latently infected cells serve as reservoirs for reactivation and as carriers of infection
to susceptible individuals [24]. After reactivation, CMV multiplies inside. In immunocompro‐
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mised patients and especially after transplantation, CMV is one of the main clinical problems
in almost all types of allograft recipients. Basic risk factor in the development CMV replication
and disease is transmission via transplanted organs or tissues including the heart, kidney, lung,
liver, and hematopoietic stem cells [25, 26]. CMV disease risk is highest when primary infection
occurs in seronegative transplant recipients by the transplanted organ from the seropositive
donor (27). On the other hand, secondary infection presumably occurs following the reactiva‐
tion of the recipient’s endogenous latent infection and is more common than primary infection.
The frequency depends on the specific immunosuppression utilized. The third type of infection
can be correlated with a presumed superinfection that is reinfection of the previously sero‐
positive recipients by donor virus present in allograft [28].
The initial infection is dangerous for all immunosuppressed patients, because of numerous
CMV indirect effects, due to the ability to modulate the immune system, and is an important
contributor to active and chronic allograft injury [26, 29]. CMV can cause dysfunction of the
transplanted organ or can participate in its rejection from the organism, which is often seen in
recipients of liver, heart, and lungs. Infections and diseases with CMV are also typical for
recipients of kidneys and bone marrow, as mortality is in the rate of 32–70%. Other risk factors
are the overall state of immunosuppression as determined by the immunosuppressive protocol
(e.g. type of drug, dose, timing, and duration), host factors (e.g. age, comorbidity, leucopenia
and lymphopenia, genetic factors), and others [30]. The degree of immunosuppression
correlates with the severity of the clinical symptoms of CMV infection. According to the data,
conventional immunosuppressive therapy is increasing the gravity of the disease.
Source of primary infection and reinfection are also blood and blood products, which have not
been checked for the presence of latent CMV virus in lymphocytes. A CMV seronegative
recipient who received donor organ of a seronegative individual has the lowest risk of CMV
disease when receiving CMV-negative blood or leuco-depleted blood products. The use of
mTOR inhibitors (everolimus, sirolimus) is associated with a lower risk of CMV disease [31].
Transplant recipients who receive treatment with lymphocyte-depleted drugs, especially if
given for the treatment of rejection, should be considered at high risk for CMV disease [32].
It is considered that in almost 100% of immunocompromised patients, the latent CMV infection
will become reactivated. This reactivation refers, especially, to recipients from seropositive
donors, although clinical manifestation is developed in 20–25 % of them [28, 33].
To assess the risk for CMV-related disease, serology testing of all donors and transplant
candidates prior to transplantation can be performed. The clinical symptoms of active CMV
infection are often nonspecific, also known as CMV syndrome (prolonged fever, weakness,
hematological abnormalities such as thrombocytopenia, atypical lymphocytosis and leukope‐
nia, and abnormalities of hepatic function). The symptoms occur 1–4 months after transplan‐
tation, in some cases, even later and sometimes it is difficult to differentiate them from those
of organ rejection. The greatest risk for this condition is at the first 30 days after the immuno‐
suppression. Tissue-invasive CMV disease is when it implicates the gastrointestinal tract,
pneumonitis, hepatitis, nephritis, myocarditis, pancreatitis, retinitis, etc. [34]. In patients with
transplanted liver, CMV hepatitis occurs in 17% of the cases. The “vanishing bile duct
syndrome” (VBS) is related with CMV infection and organ rejection. Heart and lung recipients
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usually develop interstitial pneumonia, as those with bone marrow transplantation. Mortality
is from 33–100% in a half of the patients. Atherosclerosis of coronary vessels develops three
times faster in patients with active CMV infection in heart recipients [35–42].
Laboratory diagnosis of CMV infection and CMV disease can be accomplished with various
methods. Preliminarily, before starting with the immunosuppression or transplantation, the
serological status of the donor and recipient is defined. Generally, the method used for this
purpose is ELISA, which detects specific IgG Ab in the serum of the patient. CMV infection
after transplantation represents the presence of the virus and viral replication in body fluids
or tissue samples regardless of clinical symptoms. CMV disease after transplantation repre‐
sents the presence of any clinical symptoms in patients with CMV infection [43]. The laboratory
methods to confirm CMV infections are histology, culture, serology, antigenemia (pp65
antigenemia), and molecular assay that detect and quantify CMV nucleic acid (NAT) [35].
Serology to detect CMV-IgM and IgG has limited use for diagnosis of CMV disease after
transplantation (44). Molecular tests that detect CMV DNA or RNA are the preferred methods.
Detection of CMV RNA is indicative of CMV replication. Detection of CMV DNA may or may
not reflect CMV replication since a highly sensitive NAT may amplify latent viral DNA.
Quantitative NAT (QNAT) assay have been developed to potentially differentiate active viral
replication typically associated with high viral load from latent virus with low level CMV
DNAemia [35, 45]. QNAT is useful for guiding preemptive therapy, for rapid and sensitive
diagnosis of CMV infection, and to guide treatment responses [45]. Patients suspected to have
tissue-invasive CMV disease but with negative QNAT or pp65 antgenemia should undergo
tissue biopsy and histopathology to confirm the clinical suspicion of CMV disease [35].
The approaches to CMV prevention in recipients vary among different transplant population
and risk profile. The two major strategies for CMV prevention are: antiviral prophylaxis and
preemptive therapy. Antiviral prophylaxis is the administration of antiviral drug to “at-risk”
patients for a defined period after transplantation. Preemptive therapy is the administration
of antiviral drug only to asymptomatic patients with evidence of early CMV replication in
order to prevent disease. Recipients are monitored at regular intervals (usually once weekly)
using a laboratory assay such as CMV QNAT or pp65 antgenemia.
Antiviral prophylaxis has the advantage of preventing reactivation of other herpesviruses, and
has been associated with lower incidence of indirect CMV effects [46]. Antiviral prophylaxis
can be administered to any at-risk recipients. The duration varies depending on the CMV
donor and recipient serostatus and the transplant types, extended between 100 days and 12
months in different group [35]. Valgancyclovir is the preferred drug. Alternative options are
intravenous gancyclovir, oral gancyclovir, and for kidney recipients only valacyclovir.
Unselected intravenous immunoglobulin (IVIG) may also be used but only as an adjunct to
antiviral therapy in lung, heart, and intestinal transplant recipients. In general, antiviral
prophylaxis should be started as early as possible and within the first 10 days after transplan‐
tation [35]. However, antiviral prophylaxis is associated with late-onset CMV disease partic‐
ularly among CMV D+/R- patients, probably due to development of drug resistance [47]. The
potential options for prevention and management of late-onset CMV disease are careful clinical
follow up with early treatment of CMV disease when symptoms occur, CMV QNAT or pp65
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antgenemia monitoring after completion of antiviral prophylaxis, and prolonged antiviral
prophylaxis.
Preemptive therapy requires weekly patient monitoring for evidence of early CMV replication,
which is then treated with valgancyclovir or intravenous gancyclovir. The recommended doses
are valgancyclovir (900 mg twice daily) or intravenous ganciclovir (5 mg/kg every 12 h). Many
authors prefer antiviral prophylaxis for D+/R- and lung transplant recipients while recognizing
the clinical utility of preemptive therapy in CMV R+ kidney, liver, pancreas, and heart
recipients [21, 35]. The same laboratory test for monitoring is recommended, with frequency
of once weekly for 12 weeks after transplantation.
Indications of use of ganciclovir also include severe local (often eye damages) and life threat‐
ening conditions in patients with HIV, organ transplantations, and neoplasms. The use of
lymphocyte-depleting therapy is a major risk factor for CMV disease when used for rejection
treatment. The optimal duration of antiviral prophylaxis is given for 1–3 months with valgan‐
cyclovir (900 mg once daily, oral gancyclovir 1 g p.o. thrice daily) or intravenous gancyclovir
(5 mg/kg every 24 h) [35].
Patients who develop CMV disease after prolonged courses of gancyclovir or vagancyclovir
administration, and those failing to respond to standard gancyclovir treatment, should be
suspected of having gancyclovir resistant virus. In these conditions, genotype testing should
be performed. Immunosupression should be cautiously reduced. Therapeutic options for
gancyclovir resistant CMV are limited. Foscarnet is often the first line for the treatment of UL97-
mutant gancyclovir-resistent CMV (48). Switching to sirolimus-containing regimen may be an
option for patients receiving mTOR inhibitors. Other therapeutic options are administration
of cidofovir or its new oral formulation that may be available for compassionate release
brinsidofovir (CMX001), compassionate release letermovir (AIC246), compassionate release
maribavir, off-label leflunomid and off-label artesunate [49, 50]. Due to the virus, ability to
evade host defenses of primary infection with CMV has not been shown to confer immunity
from subsequent infections. Notwithstanding this, there are efforts to develop a CMV vaccine
for prevention and therapy [51]. Due to some toxic effects of ganciclovir, patients need
preliminary tests for renal function and blood count. Renal function is defined with the means
of creatinine clearance, which has to be more than 70 ml/min. In blood, the number of neutro‐
philes has to be more than 1000 cells/mm3, platelets –above 25000 cells/mm3. During the
treatment process these indicators are monitored every week and if they begin to decrease
drastically, therapy is ceased. CMV therapy is not recommended in pregnant women, children
under 12 years old and people more than 65 years old.
4. Varicella Zoster Virus (VZV)
VZV is a human herpesvirus that spreads through direct contact with skin lesions or through
air from respiratory droplets. Primary exposure, usually in childhood, leads to varicella,
typically presents with fever, constitutional symptoms, and widely disseminated vesicular
rush that primary involves the trunk and face [52]. Symptoms usually resolve within 7–10 days
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in immunocompetent children and young adults. More than 90% of adults acquire the infection
in childhood and will be seropositive for VZV [2]. After initial infection, VZV establishes
lifelong latency in the cranial nerve and dorsal root ganglia, and can reactivate years to decades
later as herpes zoster in some individuals [53]. In children with primary and secondary
immunodeficiency because of immunosuppressive therapy (leukemia, lymphoma, solid
tumors), after transplantation VZV causes progressive varicella characterized by the continu‐
ous development of vesicular rash because of high viral replication and inadequate immune
response [54, 55]. The high mortality among these children and adult organ recipients is
because of systematic infection with multiple organ involvement, especially in the lungs, liver,
pancreas, and central nervous system and, in some cases, disseminated intravascular coagul‐
opathy. Relapses are often seen. More recent reports have shown that pediatric renal and liver
transplant recipients are at lower risk (4%–6.2%) for complication when given immediate
antiviral therapy [56–60].
Herpes zoster is characterized by vesicular rash units all over the corresponding nerve and
estimated to occur in up to 20% of the immunocompetent individuals during their lifetime. In
immunosuppressed and transplanted patients, herpes zoster is a frequent infectious compli‐
cation during the first four years after the transplantation [61, 62]. About half of the cases in
the first year after the transplantation, a disseminated infection with mortality about 9% is
observed, especially in the cases of organ rejection. Allogeneic stem cell transplantation is
another procedure that greatly heightens the risk of herpes zoster. The incidence of VZV
reactivation is 20.7%. VZV-related complications occur in 29% of patients with reactivation,
most common of which is disseminated disease and postherpetic neuralgia. Radiotherapy can
also become a reason for herpes zoster in about 15%–34 %. There is dissemination of the rash
units outside the affected dermatome. In about 1% of all cases, encephalitis develops. This is
typical, a second relapse that manifests, involving other body parts. In children with leukemia,
herpes zoster or varicella develops more than one episode of clinical manifestation. Older
transplant recipients are at greater risk for the development of herpes zoster and postherpetic
neuralgia as secondary complication [62–65].
To determine the risks of VZV primary infection or reactivation after immunosupression and
transplantation, all patients being considered for these procedures should undergo serologic
testing (ELISA anti VZV IgG) to document prior exposure to VZV. Patients who are seroneg‐
ative are at high risk for the development of primary VZV, and seropositive patients are at
high risk for developing herpes zoster. In general, both primary varicella and herpes zoster
have typical clinical presentations. Definitive laboratory testing can be used for atypical cases
and should be used for suspected disseminated, visceral disease, or central nervous system
disease. Rapid diagnostic methods, including polymerase chain reaction (PCR) and direct
immunofluorescent assay, are the methods of choice. PCR can be used for detecting VZV in
vesicle fluid, serum, spinal fluid, and other tissues. Viral culture is specific and can help
distinguish VZV from other herpesvirus pathogens (herpes simplex virus - HSV) [66].
Post-transplant and immunosuppressive patients who develop primary varicella should be
treated with intravenous (IV) acyclovir early in the course of the illness, especially within 24
hours of rash onset. Reduction of immunosuppressive therapy should be considered. How‐
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ever, IVIG or VZV immunoglobulin (VZIG) have been used in those with severe infection.
Patients with disseminated or organ invasive herpes zoster should be treated with IV acyclovir.
Localized nonsevere dermatomal herpes zoster can be treated with oral acyclovir, valacyclovir
or famcyclovir [65].
Oral acyclovir and its pro-drugs have been shown to prevent VZV reactivation in immuno‐
suppressed population. During the early post-transplant period, many current regimens used
for CMV prevention will likely prevent VZV reactivation. In patients who do not receive CMV
prophylaxis, short-term antivirals given for HSV prophylaxis may also be effective against
VZV during the period immediately post-transplant [65]. Other authors recommended one
year prophylactic with acyclovir, which has been shown to effectively prevent VZV-reactiva‐
tion after allogeneic hematopoietic stem cell transplantation [61].
In the U.S., potential transplant recipients who are susceptible to VZV should be given varicella
vaccination (one or two doses) with live attenuated Oka vaccine (Varivax, Merck & Co., Inc.,
Whitehouse Station, NJ, USA). There is currently a herpes zoster vaccine (Zostavax, Merck &
Co., Inc.) that has not been studied in patients with end-organ disease awaiting transplantation.
The Oka varicella vaccines have been shown to be safe in select children undergoing chemo‐
therapy, and studies have shown that they can be given safely to posttransplant recipients
receiving immunosupression. Inactivated VZV vaccines, which are in development, may
eventually provide another option for this high-risk population [65–68].
5. Herpes simplex virus
Herpes simplex virus type 1 (HSV1) and herpes simplex virus type 2 (HSV2) are members of
the Herpesvirus family and is transmitted via close personal contact. Seroprevalence studies
indicated that infections are common worldwide and increases with age [2, 69]. More than 90%
of adult have acquired HSV infection by their fifth decade of live, though only a minority
develop clinically apparent disease at the time of acquisition [70]. After the first contagion,
HSV stays in latent condition for a lifetime. HSV1 is acquired predominantly during childhood
age, while HSV2 is acquired by sexual contact. A recent study indicated that HSV1 can also
cause genital herpes (71). In immunocompetent individuals, symptomatic disease is presented
as orolabial or genital herpes [72, 73]. Symptomatic disease may occur as a first episode that
heals in 10–21 days, followed by the establishment of latency and the risk of subsequent
episodes of reactivation. Cell-mediated immunity plays an important role in host defense and
the containment of infection [74]. Individuals with impaired cell-mediated immunity, such as
immunosupressed and transplanted patients, are subject to more frequent episodes of
reactivation, prolonged duration of symptoms and shedding, increased severity of infection,
and a greater potential for dissemination [75]. Solid organ transplant patients have had pre-
transplant HSV seropositivity rates and age distributions similar to the general population. In
the absence of antiviral prophylaxis, seropositive recipients often experience reactivation of
latent infection within one or two months after transplantation [76]. Mucocutaneous lesions
are the majority of HSV disease in transplant population, mainly with orolabial and anogenital
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localizations. HSV esophagitis, pneumonia, meningitis, and viremia dissemination either from
reactivation or primary infection, may involve the spread to multiple organs such as the liver,
adrenal glands, gastrointestinal tract, lungs, skin, and bone marrow [77].
To determine the risk of HSV primary infection or reactivation after immunosupression and
transplantation, all patients being considered for these procedures should undergo serologic
testing (ELISA anti HSV1 IgG and anti HSV2 IgG) to document prior exposure to the viruses.
Patients who are seronegative are at high risk for the development of primary HSV, and
seropositive patients are at high risk for developing reactivation. In the presence of character‐
istic mucocutaneous lesions, clinical diagnosis may be considered reliable. Laboratory testing
can be used for atypical cases and should be used for suspected disseminated, visceral disease,
or central nervous system disease. Viral culture is the definitive method of diagnosis for
isolation of the virus from vesicles, urine, stool, nasopharynx, throat, conjunctive, and
cerebrospinal fluid. Nucleic acid amplification method of DNA detection (PCR) is increasing
utility, and has been shown to be 3 to 4 times more sensitive than viral culture [79]. Direct
fluorescent antibody test is another mode of diagnosis of HSV; it offers rapid diagnosis and
can also give type-specific diagnoses [75–79].
Acyclovir is the drug of choice for treatment of HSV infections in both immunocompetent and
immunocompromized patients. Transplant patients with mucocutaneous lesions may be
treated with IV acyclovir (5 mg/kg/dose given every 8 hours) for 7–14 days, oral acyclovir, or
one of the alternative oral antiviral agents with better bioavailability (valacyclovir or famcy‐
clovir). Disseminated infections and herpes simplex encephalitis, due to the potentially life-
threatening nature of these infections, should be treated with a high dose IV acyclovir (10 mg/
kg/dose given every 8 hours) for 7–14 days. Recently, in the last few years, some mutated
acyclovir resistant strains of HSV have been isolated. These mutants are founded in patients
with HIV and those with bone marrow transplantation and preventive treatment with
acyclovir. These patients are treated according to a scheme with pencyclovir [76]. Gancyclovi,
valgancyclovir, foscarnet or cidofovir are other antiviral agents with activity against herpes‐
viruses, including HSV and CMV co-infections. Acyclovir can also be used for prophylaxis of
the infection before immunosuppression and transplantation to prevent reactivation of the
latent infection and considerably reduced incidence of disease in the early posttransplant
period.
Numerous efforts have been made to develop an HSV vaccine using several different methods
including inactivated virus, live attenuated virus, viral subunits and more recently, recombi‐
nant viruses. Many of these attempts shower promising results in their early phase of devel‐
opment [79–80].
6. Polyomaviruses (BKV, JCV)
Polyomaviruses are ubiquitous, infecting many different mammalian species including
humans. Most human polyoma-diseases are caused by JCV and BKV. The prevalence of
infections differs in geographical and age distribution, suggesting they circulate independ‐
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ently. BKV infection is acquired in early childhood, whereas JC presents later. Transmission
of BKV occurs typically via oral and respiratory routes, but data suggests transmission via cells
and tissues, in particular by kidney transplantation [81]. Approximately 50%–80% of humans
have seropositivity to JCV and BKV viruses due to multiple routes of transmission [82, 83].
Clinically apparent diseases in immunocompetent hosts are extremely rare and are not
associated with any well-defined clinical syndrome. After primary infection, viruses remain
latent possibly in the lymphoid organs, neuronal tissue, kidney, and tubular epithelial cells.
About 5% of healthy individuals intermittently reactivate BKV replication with detectible
viruria [84]. Under the circumstances of severe immunosuppression both viruses reactivate.
BKV can cause pneumonitis, hepatitis, retinitis, and meningoencephalitis [85]. Hemorrhagic
cystitis is seen in 25–60% of bone marrow transplant patients, usually 2 weeks after transplan‐
tation [86]. Up to 80% of renal transplant patients have BK viruria, and 5%–10% progress to
BKV nephropathy (BKVN) [87]. Given that polyomavirus is widely latent in the kidney, renal
transplantation is believed to be an important mode of infection in patients with end stage
kidney disease. Graft loss rate have been reported to be as high as 30%–50% following a
diagnosis of BKVN [88]. More recent data indicate that with early diagnosis of BK viremia or
viruria using regular screening, the majority of patients respond favorably [89, 90].
Serologic testing may be used in risk-assessment of virus transmission via organ transplanta‐
tion. The greatest risk of post-transplant viral reactivation is associated with positive serostatus
of both the donor and recipient. The presence of IgG antibody to BKV-VP-1 in serum is
associated with increased risk of virus transmission and disease in renal allograft recipient [91].
To detect viral replication in urine and blood, real time PCR is the method of choice for
diagnosis of BKVN [92] and screening every 3 months for the first two years after transplant
or when allograft dysfunction occurs is recommended [93].
The first line of treatment of BKV nephropathy is reduction of immunosupression [92, 93]. A
variety of drugs with possible anti-BKV activity that are being utilized as adjuvant therapy
but fraught with side-effects are cidofovir, leflunomide, and intravenous immunoglobulin
[94]. Fluoroguinolons have been reported to display anti-BK activity because of its large T-
antigen helicase activity [95]. Further studies are needed to firmly establish the role of polyoma
viruses in human cancer [96].
Other polyomavirus with importance of human pathology is JCV. Progressive multifocal
leukoencephalopathy (PML) is a progressive demyelinating central nervous system disorder
involving cerebral white matter caused by the JCV. It most often presents as an opportunistic
infection in HIV patients with lymphopenia but has recently been seen with new immuno‐
suppressives. After reactivation in severely immunosuppressed states, the virus travels to the
central nervous system through infected B-lymphocytes, where it produces lytic destruction
of myelin producing glial cells (i.e., oligodendrocytes) and non-lytic infection of astrocytes,
causing progressive disease in central nervous system. Typical PML patients have very low
CD4+T cell counts even less than 200/mm2 [97, 98]. The estimated incidence of PML in HIV
patients is 5%, but is decreasing with the introduction of highly active anti-retroviral therapy
(HAART) [99]. The differential diagnosis of PML is HIV-associated encephalopathy and
primary CNS lymphoma. Brain biopsy is the gold standard for diagnosis. Staining with
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immunohistochemistry using antibodies directed to SV40-T antigen is confirmatory. Analysis
of cerebrospinal fluid for JCV by PCR has a sensitivity of to 92% and specificity up to 100%
(100). For patients with PML and HIV, introduction or optimization of HAART needs to be
implemented to decrease viral replication. In non-HIV patients, such as organ transplant
patients, immunosupression needs to be decreased or stopped [101]. At this stage, there is no
specific antiviral agent for JC virus [97].
7. Respiratory viruses
Every year, the number of patients undergoing stem cell and solid organ transplantation to
treat malignancy and end-organ failure increases. Despite advances in screening and prophy‐
laxis strategies, infections remain a significant cause of morbidity and mortality among
transplant recipients. From the available data, respiratory viruses remain common pathogens.
The respiratory viruses, including Adenovirus, Influenza virus, Human Metapneumovirus
(hMPV), Parainfluenza virus (PIV), Respiratory Syncytial virus (RSV), and Rhinovirus (HRV)
are increasingly recognized as contributing to significant morbidity and mortality among
hematpoietic stem cell transplant (HSCT) and solid organ transplant (SOT) recipients [102].
Iimmunocompromized patients often have atypical presentation of respiratory infections and
viral shedding can be prolonged [103]. Not one virus is exclusively associated with one clinical
syndrome and there is a high risk of infectious complications as viral pneumonia or bronchio‐
litis obliterans following acute respiratory infection. Lymphopenia is consistently a risk factor
for more serious infections. Respiratory viral infections appear to be risk factors for acute and
chronic rejection, especially in lung transplant patients [104]. There is increased risk of severe
respiratory viral infections and its sequels among pediatric recipients, as compared to adult
recipients (103).
All respiratory viruses are extremely dangerous for lung and HSCT cell recipients with high
mortality rate [105, 106]. Adenoviruses induce respiratory and gastrointestinal diseases.
Disseminated infections are characterized by fever, pneumonia, diarrhea, hemorrhagic
cystitis, hepatitis, and CNS involvement in up to 10% of the cases. In some patients Adenovi‐
ruses can become a reason for organ rejection. Cases of death can occur if there is co-infection
with CMV and different bacteria. Adenoviruses are usually in latent condition in the human
body and the infection becomes clinically manifested after reactivation of the virus (107). HRV
is probably the most common respiratory viral pathogen in the upper and lower respiratory
tract in transplant recipients [108].
In general, all patients with presumed respiratory viral infections have a nasopharyngeal swab,
wash, or brohoalbeolar aspirate performed. Diagnosis of the respiratory viruses can be
achieved by the combination of serology, virus culture, antigen detection, nucleic acid testing,
and histopathology. Serology is not useful for initial diagnosis and has reduced sensitivity in
transplant recipients. Viral culture can be achieved for most viruses except hMPV and
Coronaviruses because special cell lines are needed. Shell vial assays allow earlier detection
of viruses with application of monoclonal and polyclonal antibodies. Recently, several fixed
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mixture of cells (R-Mix) has become commercially available [109]. Rapid antigen detection
using several different techniques is available for Influenza, RSV, and Adenovirus. Direct
fluorescent antibody (DFA) testing of primary patient specimens has documented sensitivity
that approached PCR [110]. Nucleic acid amplification assay appears to be the most sensitive
diagnostic tool available, and most allow for simultaneous detection of a broad range of
respiratory pathogens from a simple sample [111].
Treatment depends on the etiological agent. Reduction of immune suppression, if possible, is
recommended for all the transplanted recipients. For infections caused by RSV, combination
therapy with aerosolized ribavirin and intravenous immunoglobulins appears to have the
greatest benefit in reducing mortality [103, 112]. PIV and hMPV infections are treated with
oral, aerosolized, or intravenous ribavirin in a combination with intravenous immunoglobu‐
lins [113]. Adenovirus infections are treated with cidofovir, vidarabin, and gancyclovir.
Lymphocyte reconstitution plays a crucial role in the clearance of Adenovirus [114]. Treatment
of Rhinovirus infections is done with pleconaril and 3C-protease inhibitors, but there is
insufficient experience with them and this limits their application. Topical interferon might be
efficacious in moderating viral shedding and symptoms [115, 116]. Prevention of Influenza
depends on aider vaccination with Influenza vaccine [117] or antiviral therapy. Vaccination is
not suitable for bone marrow transplant patients 6–12 months after the transplantation.
Patients with severe Influenza should be treated with both M2 inhibitors (rimantadin and
amantadin) and neuraminidase inhibitors (relenza and tamiflu [118].
8. Hepatitis B Virus (HBV)
Acute infection with HBV can result in fulminant hepatic failure, whereas chronic HBV
infection can lead to end-stage liver disease, including cirrhosis and hepatocellular carcinoma.
Understanding of the natural history and basic biology of HBV has increased greatly in recent
years. HBV infection is by far the most common chronic viral infection affecting the liver [119].
Reactivation of HBV replication in patients undergoing immunosuppressive therapy is well
recognized and is a frequently reported complication of considerable clinical importance [120,
121]. HBV reactivation following immunosuppression is defined by an abrupt rise in HBV
replication followed by laboratory signs of hepatocellular injury in “silent” HBV-infected
individuals (HBsAg carriers). Reactivation can also occur at a lower rate in patients with
“occult” HBV infections. The clinical presentation of reactivation is variable, ranging from an
asymptomatic course to severe hepatitis, liver failure, and death. It is most frequently observed
in patients with lymphoma treated with rituximab and corticosteroids, as well as in patients
undergoing stem cell and bone marrow transplantation. Others risk groups include patients
with solid tumors, subjects infected with HIV, organ transplant recipients, and those with
autoimmune diseases [122, 123]. It is believed that about 12% of patients with malignancy have
chronic HBV infection. In transplanted patients, infection can also reactivate after immuno‐
suppressive therapy. For these reasons, high-risk individuals should be identified and
screened. Recommendation for screening for all three serologies, including HBcAb, HBsAg,
and HBsAb in those planned for immunosuppression is available [124]. Despite advances in
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treatment of chronic HBV infection, liver transplantation remains the only hope for many HBV-
related end-stage liver disease patients. The high rate of HBV reinfection or recurrence after
liver transplantation is probably due to enhanced virus replication resulting from immuno‐
suppression and other mechanisms. In the recent years, liver transplantation has shown
encouraging results. The introduction of effective measures to prevent and treat reinfection or
recurrence using strategies involving hepatitis B immune globulin (HBIG) and subsequently
nucleos(t)ide analogues have significantly improved the outcome of liver transplantation [125,
126]. Overall HBsAg positive patients who are candidates for chemotherapy or treatment with
biological agents, preemptive treatment with an antiviral agents such as lamivudine, and lately
with the more potent tenofovir, entecavir, or adefovir, has become a standard of care, effec‐
tively preventing HBV reactivation. Patients with occult HBV should be monitored for alanine
aminotransferase and HBV DNA (by real-time PCR) during the course of immunosuppression.
Prompt administration of a potent antiviral agent upon diagnosis of reactivation may be
lifesaving in such patients [122].
9. Hepatitis C Virus (HCV)
Infections with HCV can result in both acute and chronic hepatitis. Acute HCV typically leads
to chronic infection in about 80% of cases. This condition leads to both extrahepatic and hepatic
disorders, mainly chronic liver inflammation, cirrhosis and liver cancer [127, 128]. Chronic
HCV infection is usually slowly progressive. Approximately 20% to 30% of chronic-infected
individuals develop cirrhosis over a 20–30-year period of time. HCV-associated cirrhosis is the
most common indication for orthotopic liver transplantation among adults. It is well docu‐
mented, that recurrence of HCV and reinfection of the graft following liver transplantation
more frequently occurs. The observations indicate that up to 40% of the patients experience
recurrent hepatitis and cirrhosis 5 years later [129]. This progression depends on the age of the
donor (below 40 years old), the gravity of the immunosuppression, viral status of the patient
before transplantation and a month after it. Prevention and treatment of HCV reinfection and
reactivation after liver transplantation remains an unsolved major clinical challenge. HCV-
positive patients have poorer long-term outcomes after liver transplantation in comparison
with patients with other underlying liver diseases. While treatment with pegilated interferon
alpha and ribavirin can cure up to one-third of HCV-positive transplanted patients, there are
many promising drugs in clinical and preclinical development targeting either the virion or
essential host factors. New strategies to prevent HCV reinfection include neutralizing anti‐
bodies or drugs targeting cellular HCV entry factors. Unfortunately, it will take at least several
years until most of these drugs will reach routine clinical practice.
The relationship between HCV infection and immunosuppression is complex. The complexity
is further complicated by the intrinsic tendency of HCV infection in itself to lead to disorders
of the immune system. After HCV discovery, it was shown that HCV is also a lymphotropic
virus, and as a consequence of lymphatic infection, several lymphoproliferative disorders have
been associated. Although HCV-related hepatocytolysis is classically interpreted as secondary
to attack by cytotoxic T-lymphocytes against infected cells, the liver disease is usually exacer‐
bated and more rapidly evolutive in immunosuppressed patients [130, 131]. Liver disease
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secondary to chronic HCV infection is an important cause of morbidity and mortality in
dialysis patients and kidney transplant recipients. Eradication of infection before transplan‐
tation seems to reduce the risk for HCV-associated renal dysfunction after transplantation, and
may reduce risk of HCV disease progression. For dialysis patients, ribavirtin is generally
contraindicated and alternatives are needed to enhance antiviral effects of interferon. New
therapies with taribavirin may offer specific advantage in this patient group [132, 133]. In
individuals with defects in cell-mediated immunity, predominantly CD4Th1, occurring in HIV
infection and in patients requiring multi-drug immunosuppression following solid organ
transplantation, chronic liver disease caused by HCV progresses more rapidly than in
immunocompetent individuals. The rate of progress seems to correlate with the degree of
immunosuppression. The prolonged suppressive therapy aggravates liver function [134].
Liver-related mortality is higher in those patients who are co-infected with HCV and HIV. All
immunosuppressed and HIV infected patients should be screened for HCV infection using
sensitive immunoassay licensed for detection of antibodies to HCV. For laboratory tests, ELISA
is most widely used from the serological methods. HCV seropositive patients should be tested
for HCV RNA using a sensitive quantitative assay to confirm the presence of active infection
by RT PCR. Patients with positive HCV-RNA test should be genotyped and should be
evaluated for HCV therapy [134, 135]. Liver disease in an immunosuppressed patient is
typically severe with unusual progression to cirrhosis. However, accurate screening and
specialized advice is recommended as soon as possible in HCV-positive patients.
For the last few years, there has been great progress in the production and application of drugs
for prophylaxis and treatment of latent and chronic viral infections in immunosuppressed and
transplanted patients. Various schemes for drug usage have been developed and have been
permanently completed. Immunosuppressed patients very often are affected with nosocomial
infections in hospitals, and with infections in the society. For this reason, accurate screening
and prompt and precise diagnosis can be performed to prevent exacerbation of diseases and
provide appropriate treatment.
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